Dextrin Or Derivative Patents (Class 536/103)
  • Patent number: 10577433
    Abstract: The present application provides an improved process for the preparation of sugammadex by reacting a salt of 3-mercapto propionic acid with 6-per-deoxy-6-per-halo-?-cyclodextrin in a suitable organic solvent. This application also provides crystalline form of a salt of 3-mercapto propionic acid, preferably di sodium salt of 3-mercapto propionic acid and its use for the preparation of sugammadex, whereas formula (I) shows the sodium salt of sugammadex.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: March 3, 2020
    Assignee: Fresenius Kabi iPSUM S.r.l.
    Inventors: Walter Cabri, Antonio Ricci, Jacopo Zanon, Saswata Lahiri, Govind Singh, Shivaji Haribhau Shelke, Tapanjyoti Biswal, Nitin Kumar, Madan Singh
  • Patent number: 10494450
    Abstract: The present invention relates to a process for preparation of 6-perdeoxy-6-per-chloro gamma-cyclodextrin which is a key intermediate useful in the synthesis of Sugammadex sodium. The present invention further relates to a process for preparation and purification of Sugammadex sodium.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: December 3, 2019
    Inventor: Lakshmi Prasad Alaparthi
  • Patent number: 10385142
    Abstract: A process for preparing sugammadex sodium comprising: reacting a ?-cyclodextrin of formula I with a halogenating agent in the presence of N-methyl-2-pyrrolidone to provide a compound of formula II; and reacting the compound of formula II with 3-mercapto propionic acid in the presence of a sodium base and an organic solvent to provide sugammadex sodium formula III: wherein X in formula II is halo.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: August 20, 2019
    Assignee: SCINOPHARM TAIWAN, LTD.
    Inventors: ChiaYing Lee, ShangHong Chen
  • Patent number: 10125016
    Abstract: Disclosed are cyclodextrin-based metal organic frameworks comprising a metal cation and cyclodextrin or a cyclodextrin derivative. These metal organic frameworks are permanently porous and capable of molecule storage.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: November 13, 2018
    Assignee: Northwestern University
    Inventors: J. Fraser Stoddart, Ronald A. Smaldone, Ross S. Forgan, Jeremiah J. Gassensmith
  • Patent number: 9580518
    Abstract: A method for fractionating dextrin, belonging to the technical field of food processing. In principle, the method for fractionating dextrin of the present invention is based on the fact that the dextrin is incompatible with polyethylene glycol in aqueous solution and a larger molecular weight of the dextrin results in more significant incompatibility with polyethylene glycol. Accordingly, the stepwise precipitation of dextrin components having a molecular weight from large to small may be realized by gradually increasing the concentration of polyethylene glycol by gradually adding polyethylene glycol to dextrin in aqueous solution.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: February 28, 2017
    Assignee: Jiangnan University
    Inventors: Zhengyu Jin, Yaoqi Tian, Xiuting Hu, Binghua Sun, Bao Zhang, Benxi Wei, Chunsen Wu, Na Yang, Xueming Xu
  • Patent number: 9358205
    Abstract: A controlled-release oral pharmaceutical composition of at least an active agent, including: a) a lipophilic matrix consisting of lipophilic compounds and/or amphiphilic compounds; and b) an hydrophilic matrix, wherein the hydrophilic matrix includes at least an indigestible polysaccharide, the active ingredient being dispersed in the lipophilic and/or the hydrophilic matrix. The present invention also relates to a process for the preparation of such a pharmaceutical composition.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: June 7, 2016
    Assignee: Roquette Freres
    Inventors: Olaf Haeusler, Marie-Helene DeGrave, Daniel Wils, Stefanie Krenzlin, Juergen Siepmann
  • Patent number: 9232816
    Abstract: The present invention relates to a fibrous starch with enhanced emulsifying capacity and emulsifying stability, and low-fat mayonnaise and margarine compositions using the same. More specifically, disclosed are fibrous starch which has an increased starch particle size and exhibits improved emulsifying capacity and emulsion stability, prepared by heat-treating starch at a temperature lower than a gelatinization temperature, phosphorylating the starch and further heat-treating the starch sample at a high temperature, and low-fat mayonnaise and margarine compositions in which the content of cooking oil is reduced by 50% or more by adding the fibrous starch with enhanced emulsifying capacity thereto.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: January 12, 2016
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Jin Hee Park, Ah Jin Kim, Sung Bae Byun, Sang Hoon Song
  • Patent number: 9085460
    Abstract: Disclosed are cyclodextrin-based metal organic frameworks comprising a metal cation and cyclodextrin or a cyclodextrin derivative. These metal organic frameworks are permanently porous and capable of molecule storage.
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: July 21, 2015
    Assignee: Northwestern University
    Inventors: J. Fraser Stoddart, Ross S. Forgan, Ronald A. Smaldone, Jeremiah J. Gassensmith
  • Publication number: 20150108064
    Abstract: The present invention relates to channel type cyclodextrin crystals, particularly channel type ?-cyclodextrin crystals, to a method for producing channel type cyclodextrin crystals, and products comprising channel type cyclodextrin crystals.
    Type: Application
    Filed: March 13, 2013
    Publication date: April 23, 2015
    Inventors: Kim Lambertsen Larsen, Ronnie Nielsen, Thuy Thanh Do
  • Patent number: 8999953
    Abstract: The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: April 7, 2015
    Assignee: Oculis EHF
    Inventors: Thorsteinn Loftsson, Einar Stefansson
  • Publication number: 20150087822
    Abstract: The invention relates to a complex of pure anthocyanidin and a sulfoalkyl ether ?-cyclodextrin, which complex can be formulated as an aqueous solution and as a solid, and a method for producing such a complex. Complexes according to the invention are storage-stable and can be well formulated as an aqueous solution.
    Type: Application
    Filed: March 28, 2013
    Publication date: March 26, 2015
    Inventors: Norbert Roewer, Jens Broscheit
  • Patent number: 8987230
    Abstract: The present invention provides a composition comprising a hyaluronic acid derivative having a crosslinking group(s) and a hydrophilic polysaccharide derivative having a hydrophobic group(s), wherein the hyaluronic acid derivative having a crosslinking group(s) is prepared by crosslinkage formation reaction in hyaluronic acid or a derivative thereof having a crosslinkable group(s) in the presence of the hydrophilic polysaccharide derivative wherein the hydrophilic polysaccharide derivative may have a crosslinkable group(s).
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: March 24, 2015
    Assignees: National University Corporation Tokyo Medical and Dental University, Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kazunari Akiyoshi, Nobuyuki Morimoto, Tai Hirakura, Tsuyoshi Shimoboji
  • Publication number: 20150051390
    Abstract: The invention provides a method of producing a polyrotaxane having cyclic molecules, a linear molecule threaded through the cyclic molecules to form a clathrate, and blocking groups at both ends of the linear molecule to prevent the separation of the cyclic molecules from the linear molecule, the method including forming the blocking groups by reacting the linear molecule piercing the cyclic molecules, the linear molecule having carboxyl groups at both ends thereof, with a blocking agent having an amino group in the absence of a solvent or in at least one organic solvent selected from the group consisting of aprotic amide solvents and aromatic hydrocarbons, and further in the presence of 2.0 mol to 100 mol of a triazine-based amidating agent per 1 mol of the carboxyl groups in the linear molecule.
    Type: Application
    Filed: April 1, 2013
    Publication date: February 19, 2015
    Applicants: UBE INDUSTRIES, LTD., ADVANCED SOFTMATERIALS INC.
    Inventors: Naoyuki Yokota, Kenji Arimitsu, Akio Matsushita, Yoshitaka Ooue, Mikio Fujimoto, Yasunori Fukuda, Minoru Iwata, Yuki Hayashi
  • Publication number: 20150050355
    Abstract: A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAECD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.
    Type: Application
    Filed: September 17, 2014
    Publication date: February 19, 2015
    Inventors: James D. Pipkin, Gerold L. Mosher, Douglas B. Hecker
  • Patent number: 8956816
    Abstract: Methods for performing analytical reactions and compositions for use in such methods, where the methods have reduced signal levels deriving from non-specific adsorption of detected reagents to other components of the analytical method, e.g., other reagents, solid phase components, vessels, etc.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: February 17, 2015
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Andrei Fedorov, Stephen Yue, Lei Sun, Gene Shen, John Lyle
  • Publication number: 20150030683
    Abstract: In certain embodiments the methods of preventing or delaying the onset of a pre-Alzheimer's condition and/or cognitive dysfunction, and/or ameliorating one or more symptoms of a pre-Alzheimer's cognitive dysfunction, and/or preventing or delaying the progression of a pre-Alzheimer's condition or cognitive dysfunction to Alzheimer's disease, and/or of promoting the processing of amyloid precursor protein (APP) by the non-amyloidogenic pathway are provided. In certain embodiments the methods involve administering, or causing to be administered, to a subject in need thereof certain formulations comprising or more active agent(s) selected from the group consisting of tropisetron disulfiram, honokiol, nimetazepam, and/or derivatives or analogs thereof.
    Type: Application
    Filed: February 15, 2013
    Publication date: January 29, 2015
    Inventors: Varghese John, Dale E. Bredesen, Stelios Tzannis
  • Publication number: 20150025037
    Abstract: Hyper-branched maltodextrins having a dextrose equivalent (DE) between at least 8 and at most 15 and a molecular weight or Mw between at least 1,700 and at most 3,000 daltons, characterized in that same have: a 1,6 glucoside bond content between at least 30 and at most 45%; a soluble indigestible fiber content, which is determined according to the AOAC No. 2001-03 method, between at least 75 and at most 100%; and a hypoglycemic capacity expressed according to a test A, which:—in vitro, results in an 80 to 90% reduction of the ?-amylase hydrolysis of standard maltodextrins, and—in situ, by a 30 to 45% reduction in the intestinal digestive activity of standard maltodextrins.
    Type: Application
    Filed: February 27, 2013
    Publication date: January 22, 2015
    Applicant: ROQUETTE FRERES
    Inventors: Stèphanie Bureau, Laëtitia Guerin-Deremaux, Bernard Pora
  • Publication number: 20150011003
    Abstract: A medium which comprises a fibroblast growth factor (FGF), and a sulfated compound or a pharmaceutically acceptable salt thereof at a concentration which promotes the growth of a stem cell in the presence of FGF, is useful for culturing stem cells.
    Type: Application
    Filed: September 26, 2014
    Publication date: January 8, 2015
    Applicant: AJINOMOTO CO., INC.
    Inventors: Yoko KURIYAMA, Nao SUGIMOTO, Manabu KITAZAWA, Satoru OKAMOTO, Sho SENDA, Ikue HARATA, Satoru OHASHI
  • Publication number: 20150005487
    Abstract: The present invention relates to a sorbent comprising a solid support material, the surface of which comprises a residue of a general formula (I), wherein the residue is attached via a covalent single bond to a functional group on the surface of either the bulk solid support material itself or of a polymer film on the surface of the solid support material. Furthermore, the present invention relates to the use of the sorbent according to the invention for the purification of organic molecules, in particular pharmaceutically active compounds, preferably in chromatographic application.
    Type: Application
    Filed: September 17, 2012
    Publication date: January 1, 2015
    Applicant: INSTRACTION GMBH
    Inventors: Markus Arendt, Björn Degel, Thomas Schwarz, Gerhard Stumm, Martin Welter
  • Publication number: 20140377207
    Abstract: Absorbent articles comprising one or more complexed or encapsulated compounds compounds selected from: melonal, adoxal, trans-2-hexenal, ligustral, Floral Super, Florhydral, 5-methyl-2-thiophene-carboxaldehyde, hydratropic aldehyde, undecenal, 9-undecenal, 10-undecenal, trans-4-decenal, cis-6-nonenal, isocyclocitral, precyclemone b, (E)-2,(z)-6-nonadienal, undecyl aldehyde, methyl-octyl-acetaldehyde, Lauric aldehyde, silvial, vanillin, floralozone; are particularly effective in reducing malodors coming from degradation of proteinaceous materials such as food, menses or feces.
    Type: Application
    Filed: June 19, 2014
    Publication date: December 25, 2014
    Inventors: Timothy Alan Scavone, Misael Omar Aviles, Brian Francis Gray, Peter Christopher Ellingson, Dean Larry Duval
  • Patent number: 8889398
    Abstract: The present invention relates generally to the field of prevention of diseases caused by enveloped viruses. More particularly, this invention concerns a composition for inactivating an enveloped virus comprising at least one non phospholipid Lipid Vesicle (nPLV) able to interact with said enveloped virus and an agent that enhances the lipid exchange between said nPLV and the membrane of said enveloped virus.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: November 18, 2014
    Assignee: Viroblock SA
    Inventors: Thierry Pelet, Francesca A. Wallach
  • Publication number: 20140335152
    Abstract: The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a regulating agent of lipid raft/caveolae-dependent endocytic pathway and some therapeutic agents, such as anti-tumor agents. The invention also relates to a method for screening a regulating agent of lipid raft/caveolae-dependent endocytic pathway capable of enhancing the therapeutic efficacy of anti-tumor agents.
    Type: Application
    Filed: March 28, 2012
    Publication date: November 13, 2014
    Applicants: TSINGHUA UNIVERSITY, BEIJING PROTGEN LTD.
    Inventors: Yongzhang LUO, Yang CHEN, Yan FU, Lin JIA, Guodong CHANG
  • Patent number: 8871740
    Abstract: The present invention relates to a composition including a mix of a polysaccharides having: 15% to 50% of glucoside linkages 1-6; a reducing sugar content of less than 20%; a polymolecularity index of less than 5; an average molecular weight with number Mn of less than 4500 g/mole and at least one active agent for treating stress, anxiety and depressive behavior, sleep disorders, obsessive-compulsive disorder, bulimia and epilepsy in humans or animals. The present invention also relates to the use of the polysaccharide for treating stress, anxiety or depressive behavior, sleep disorders, obsessive-compulsive disorder, bulimia and epilepsy in humans or animals.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: October 28, 2014
    Assignee: Roquette Freres
    Inventors: Laetitia Guerin-Deremaux, Daniel Wils
  • Patent number: 8871473
    Abstract: The present invention provides a method for the production of ?-CD, comprising making a starch slurry, incubating with ?-CGTase and isoamylase simultaneously for ?-CD production, forming a complex of ?-CD and an organic complexant, and purifying ?-CD from the complexant. The present invention provides a simple and cost-effective method for producing high purity ?-CD, which has a short production cycle, a high conversion rate, and is adaptable to large-scale industrial production.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: October 28, 2014
    Assignee: Jiangnan University
    Inventor: Jing Wu
  • Patent number: 8865887
    Abstract: The present invention relates to a novel method for synthesizing a composition of polymers, copolymers, terpolymers and tetrapolymers, and to the use thereof, said composition being made from: cyclodextrins, in particular ?-cyclodextrin, ?-cyclodextrin, ?-cyclodextrin, the derivatives or corresponding mixtures thereof, and/or calix[n]arene(s) and/or of calix[n]arene derivative(s) and/or a mixture of two or more different calix[n]arenes selected from calix[n]arenes (n=4-20) and/or the derivatives thereof, and to the uses thereof. A method was developed on the basis of direct-melt polycondensation. The invention can be used in the pharmaceutical, human medicine, veterinary medicine, chemistry, separation chemistry, environmental, electronics, biological, diagnostics, phytosanitation, medicinal food, agri-food, and cosmetics fields, and in the nutraceutical field and in the field of molecular imprints (MIP).
    Type: Grant
    Filed: December 27, 2010
    Date of Patent: October 21, 2014
    Inventor: Mohamed Skiba
  • Publication number: 20140296180
    Abstract: Compounds which inhibit Wza-mcdiated polysaccharide transport are useful in the prevention or treatment of bacterial infection, in particular of E. coli infection. The compounds are typically cyclic oligosaccharides such as cyclodextrins, which bear positively charged functional groups at the primary carbon position.
    Type: Application
    Filed: August 20, 2012
    Publication date: October 2, 2014
    Applicant: ISIS INNOVATION LIMITED
    Inventors: Lingbing Kong, Benjamin G. Davis, Hagan Bayley
  • Patent number: 8815301
    Abstract: The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: August 26, 2014
    Assignee: Pharmacosmos Holding A/S
    Inventor: Hans Andreasen
  • Publication number: 20140231352
    Abstract: Provided is a silica particle coated with ?-cyclodextrin, wherein said cyclodextrin is attached to said silica particle via at least one crosslinking agent and/or at least one copolymer. Also provided are methods of removing contaminants from a flowing or stationary liquid phase comprising the step of contacting said liquid phase with the silica particle coated with ?-cyclodextrin.
    Type: Application
    Filed: October 17, 2012
    Publication date: August 21, 2014
    Applicant: TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Rominder P. S. Suri, Bikash Bhattarai
  • Publication number: 20140228318
    Abstract: The present invention provides cyclodextrin-curcumin inclusion complexes, self-assemblies thereof; methods for making such inclusion complexes and self-assemblies, and methods for their use.
    Type: Application
    Filed: July 15, 2011
    Publication date: August 14, 2014
    Applicant: Sanford Research/USD
    Inventors: Subhash Chauhan, Meena Jaggi, Murali Mohan Yallapu
  • Patent number: 8802653
    Abstract: A deodorant composition contains ?-cyclodextrin, a fixative, a preservative, and a solvent.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: August 12, 2014
    Assignee: C.B. Fleet Company, Inc.
    Inventors: Nelson Ayala, Ruby Anderson
  • Publication number: 20140220080
    Abstract: Provided is a novel IgA secretion promoter useful as a mucosal immunity stimulation agent and a method of promoting IgA secretion in a body of animal to stimulate mucosal immunity. A significant action of promoting IgA secretion was observed in oral administration of indigestible dextrin.
    Type: Application
    Filed: April 26, 2013
    Publication date: August 7, 2014
    Inventors: Shoko MIYAZATO, Yuka KISHIMOTO, Akira HOSONO, Kyoko TAKAHASHI, Shuichi KAMINOGAWA
  • Publication number: 20140221641
    Abstract: A novel process for the preparation of 6-perdeoxy-6-per-halo Gamma cyclodextrin which is a useful intermediate in the synthesis of Suggamadex is disclosed in the invention. The process involves by reacting Gamma cyclodextrin with phosphorous halide in presence of organic solvent.
    Type: Application
    Filed: August 23, 2011
    Publication date: August 7, 2014
    Inventors: Ramamohan Rao Davuluri, Ravi Ponnaiah, Ravi Kanth Sribhashyam, Nandkumar Mecherili Valsan, Naresh Dongari, Prasad Chlnv, Guruswamy Batthini
  • Publication number: 20140206860
    Abstract: Fabrication and arrangement of nanoparticles into one-dimensional linear chains is achieved by successive chemical reactions, each reaction adding one or more nanoparticles by building onto exposed, unprotected linker functionalities. Optionally, protecting groups may be used to control and organize growth. Nanoparticle spheres are functionalized in a controlled manner in order to enable covalent linkages. Functionalization of nanoparticles is accomplished by either ligand exchange or chemical modification of the terminal functional groups of the capping ligand. Nanoparticle chains are obtained by a variety of connectivity modes such as direct coupling, use of linker molecules, and use of linear polymeric templates. In particular, a versatile building block system is obtained through controlled monofunctionalization of nanoparticles.
    Type: Application
    Filed: October 22, 2013
    Publication date: July 24, 2014
    Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Joseph M. Jacobson, David W. Mosley, Kie-Moon Sung
  • Publication number: 20140199370
    Abstract: This application discloses cyclodextrin-modified materials for carrying drugs and other active agents, such as nucleic acids. Compositions are also disclosed of cyclodextrin-modified materials that release such active agents under controlled conditions. The invention also discloses compositions of cyclodextrin-modified polymer carriers that are coupled to biorecognition molecules for assisting the delivery of drugs to their site of action.
    Type: Application
    Filed: August 15, 2013
    Publication date: July 17, 2014
    Applicant: CERULEAN PHARMA INC.
    Inventors: Suzie Hwang Pun, Nathalie C. Bellocq, Mark E. Davis
  • Publication number: 20140200290
    Abstract: Hydrophilic coating compositions and methods to make and use the compositions are disclosed. The coatings include one or more amphiphilic cyclodextrins, with one or more hydrophilic groups in place of primary hydroxyl groups, and one or more hydrophobic groups in place of secondary hydroxyl groups. The hydrophobic surface of the cyclodextrin faces the binder particles, while the hydrophilic surface is exposed to the exterior, thus providing a hydrophilic and self-cleaning property to the coating.
    Type: Application
    Filed: October 12, 2012
    Publication date: July 17, 2014
    Inventor: Glen Leon Brizius
  • Publication number: 20140171388
    Abstract: The present invention provides a compound of which active |form| is represented by a formula (A). and which can be injected into a joint cavity which is an affected part of disorders and can be accumulated in the joint cavity to exert the pharmacological effect thereof in a sustained manner, for the purpose of ameliorating cartilage disorders without developing any side effect. A compound according to the present invention, which is represented by a formula (I): (wherein all of symbols are as defined in the description), is a compound that can achieve the above-mentioned purpose. This compound does not exhibit any side effect on the cardiovascular system even when the compound is administered in an effective amount for exhibiting a cartilage regeneration activity, and is therefore extremely useful as a safe and effective preventive and/or therapeutic agent for cartilage disorders.
    Type: Application
    Filed: August 3, 2012
    Publication date: June 19, 2014
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuo Obitsi, Kousuke Tani, Hikaru Sugihara, Akio Nishiura, Shinsei Fujimura
  • Publication number: 20140155348
    Abstract: The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-?-cyclodextrin or sulfobutylether-7-?-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis.
    Type: Application
    Filed: June 24, 2013
    Publication date: June 5, 2014
    Applicant: Zafgen, Inc.
    Inventors: Jae Hyun Kim, Su Kyung Lee, Won Kyu Choi, Jong Lae Lim, Soon Kil Ahn, Hee Jong Shin, Chung Il Hong
  • Publication number: 20140147492
    Abstract: The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a regulating agent of lipid raft/caveolae-dependent endocytic pathway and some therapeutic agents, such as anti-tumor agents. The invention also relates to a method for screening a regulating agent of lipid raft/caveolae-dependent endocytic pathway capable of enhancing the therapeutic efficacy of anti-tumor agents.
    Type: Application
    Filed: March 28, 2012
    Publication date: May 29, 2014
    Applicant: TSINGHUA UNIVERSITY
    Inventors: Yongzhang Luo, Yang Chen, Yan Fu, Lin Jia, Guodong Chang
  • Patent number: 8735374
    Abstract: A direct compression formulation suitable for preparing buccal and/or sublingual and dosage forms incorporates a combination of a non-ionic polymeric solubility enhancer, a mucoadhesive polymer, a filler, a disintegrant, and a pharmaceutically active agent. Cannabinoid-cyclodextrin complexes exhibiting an improved property selected from improved stability, higher product yield and improved product uniformity may be obtained by complexing the cannabinoid with the cyclodextrin in a liquid medium containing an antioxidant. To enhance stability, product yield and/or product uniformity, complexing may be done while the liquid medium is in contact with an atmosphere having a very low oxygen content.
    Type: Grant
    Filed: July 15, 2010
    Date of Patent: May 27, 2014
    Assignee: Intelgenx Corp.
    Inventors: Horst G. Zerbe, Nadine Paiement
  • Publication number: 20140142292
    Abstract: A (meth)allylsilane compound chemically bonded to various alcohol derivatives including polyol derivatives such as saccharides, is raw material used to cause a substrate to express functionalities such as a defogging property and separation characteristics for column chromatography, can be easily prepared, is easily purified, and is stable and easy to handle, and a functional material in which those functionalities are expressed, while silyl group-containing groups are conveniently carried at a high density on the surface of the substrate, by using the (meth)allylsilane compound as a silane coupling agent for silane-coupling to the substrate. The (meth)allylsilane compound includes a (meth)allylsilyl group-containing alkyl group or a (meth)allylsilylalkyl group-containing aralkyl group that is bonded to an alcohol derivative.
    Type: Application
    Filed: June 28, 2012
    Publication date: May 22, 2014
    Applicants: DAICEL CORPORATION, KYOEISHA CHEMICAL CO., LTD.
    Inventor: Toyoshi Shimada
  • Publication number: 20140128343
    Abstract: A stable complex of tomoxiprole with 2-hydroxypropyl-beta-cyclodextrin with fast dissolution rate and rapid absorption wherein amorphous tomoxiprole forms a complex with 2-hydroxypropyl-beta-cyclodextrin in about equimolecular ratio. The complex shows a remarkably faster dissolution rate and absorption with respect to crystalline tomoxiprole and is particularly suitable for the production of pharmaceutical oral dosage forms, such as tablets and capsules, where rapid onset of therapeutical action is required. A method of manufacture of the complex is also described and claimed.
    Type: Application
    Filed: June 14, 2012
    Publication date: May 8, 2014
    Applicants: FONDAZIONE CARIPLO, FONDAZIONE ISTITUTO INSUBRICO DI RICERCA PER LA VITA
    Inventors: Alberto Milanese, Marino Nebuloni, Lucia Carrano
  • Publication number: 20140113977
    Abstract: This disclosure relates to cyclodextrin-based drug delivery agents that comprise a cyclodextrin moiety covalently linked to a moiety of a gemini surfactant. Pharmaceutical compositions comprising the drug delivery agent and a therapeutic agent are also disclosed.
    Type: Application
    Filed: May 18, 2012
    Publication date: April 24, 2014
    Applicant: University of Saskatchewan
    Inventors: Ildiko Badea, Ronald Verrall, Peng Yang, Marianna Foldvari, Jackson Chitanda, Deborah Michel
  • Publication number: 20140100363
    Abstract: Certain exemplary embodiments can provide a composition of matter comprising a solid form of chlorine dioxide complexed with a cyclodextrin. The concentration of chlorine dioxide in said solid form is greater than approximately 5.8 percent by weight. Certain exemplary embodiments can provide a method comprising forming a solid complex comprising chlorine dioxide and cyclodextrin, wherein a concentration of chlorine dioxide in the solid complex is greater than 5.8 percent by weight.
    Type: Application
    Filed: December 12, 2013
    Publication date: April 10, 2014
    Applicant: Dharma IP, LLC
    Inventors: Nick Blandford, Ken Harrison
  • Publication number: 20140094433
    Abstract: Compositions, such as hydrogel compositions, that include a hyaluronic acid, a vitamin A, and a cyclodextrin may be used as medical or cosmetic fillers, implants, or creams. For example, the compositions may be used as dermal fillers.
    Type: Application
    Filed: October 1, 2013
    Publication date: April 3, 2014
    Applicant: Allergan, Inc.
    Inventors: Futian Liu, Xiaojie Yu, Nicholas J. Manesis
  • Publication number: 20140094432
    Abstract: Processes for precipitating polymers from a polymer-containing solution are disclosed.
    Type: Application
    Filed: October 1, 2013
    Publication date: April 3, 2014
    Applicant: CERULEAN PHARMA INC.
    Inventor: J. Michael Ramstack
  • Publication number: 20140080936
    Abstract: The present invention relates to a novel polyrotaxane compound having a specific chemical structure, a photocurable coating composition that may provide a coating material having excellent mechanical properties such as scratch resistance, chemical resistance, abrasion resistance, and the like, and excellent self-healing capability, and a coating film obtained from the photocurable coating composition.
    Type: Application
    Filed: September 6, 2013
    Publication date: March 20, 2014
    Applicant: LG CHEM, LTD.
    Inventors: Heon KIM, Yeong-Rae CHANG, Hye-Min KIM
  • Publication number: 20140066615
    Abstract: The present invention aims to provide a method of producing a powdered hydrophilic modified polyrotaxane, which enables production of a powdered hydrophilic modified polyrotaxane excellent in storage stability in an industrially advantageous way.
    Type: Application
    Filed: December 5, 2011
    Publication date: March 6, 2014
    Applicants: ADVANCED SOFTMATERIALS INC., SUMITOMO SEIKA CHEMICALS CO., LTD.
    Inventors: Tomoaki Yamasaki, Shinya Okazaki, Hiroki Okazaki, Shigeki Hamamoto, Yuki Hayashi, Minoru Iwata
  • Publication number: 20140058078
    Abstract: The present invention aims to provide a polyrotaxane composition having excellent storage stability. The present invention relates to a polyrotaxane composition comprising: a polyrotaxane containing a cyclodextrin, a polyethylene glycol which is included in the cavities of the cyclodextrin molecules in a skewered manner, and a capping group that is placed at each end of the polyethylene glycol and prevents dissociation of the cyclodextrin molecules from the polyethylene glycol; and a polyphenol antioxidant.
    Type: Application
    Filed: December 5, 2011
    Publication date: February 27, 2014
    Applicants: ADVANCED SOFTMATERIALS INC., SUMITOMO SEIKA CHEMICALS CO., LTD.
    Inventors: Tomoaki Yamasaki, Shinya Okazaki, Hiroki Okazaki, Shigeki Hamamoto, Changming Zhao, Minoru Iwata, Yuki Hayashi
  • Publication number: 20140044669
    Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.
    Type: Application
    Filed: October 17, 2013
    Publication date: February 13, 2014
    Applicant: CERULEAN PHARMA INC.
    Inventors: Jianjun Cheng, Mark E. Davis, Kay T. Khin
  • Patent number: RE44733
    Abstract: Disclosed is a 6-mercapto-cyclodextrin derivative having general formula (I) wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C1-6)alkylene, optionally substituated with 1-3 OH groups, or (CH2)o-phenylene-(CH2)p—; o and p are independently 0-4; X is COOH, CONHR1, NHCOR2, SO2OH, PO(OH)2, O(CH2—CH2—O)q—H, OH or tetrazol-5-yl; R1 is H or (C1-3)alkyl; R2 is carboxyphenyl; q is 1-3; or pharmaceutically acceptable salts thereof. The 6-mercaptocyclodextrin derivative is highly suitable for use in the reversal of drug-induced neuromuscular block.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: January 28, 2014
    Assignee: Merck Sharp & Dohme B.V.
    Inventors: Mingiang Zhang, Ronald Palin, Jonathan Bennett